ClinicalTrials.gg
CompletedNCT04320030EITHICSUpdated Nov 10, 2026Results posted

[18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers

A Phase 2 interventional study of [18F]-DPA-714 in Triple Negative Breast Cancer, sponsored by Institut Cancerologie de l'Ouest. Completed at 3 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Institut Cancerologie de l'Ouest · Phase 2, Interventional, and Diagnostic

How we know

Updated Nov 10, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 125 studies in Triple Negative Breast Neoplasms with a site in France — 35 open to participants now, 66 under way, 13 of them phase 3. Triple Negative Breast Neoplasms · France.

Enrollment
113th of 119
13 · median 182
Started
2020
with 13 others
Phase 2
25 of 125
5 open now
Registered
55th of 125
by date

Among the 125 studies in Triple Negative Breast Neoplasms with a site in France, this one is the 113th largest by enrollment of the 119 interventional ones that give a count, is one of 14 that started in 2020, is one of 25 in phase 2, and was the 55th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

35 of the 125 studies in Triple Negative Breast Neoplasms with a site in France are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Triple Negative Breast Neoplasms with a site in France, or all of them as a file.
02

Study summary

This phase II study is assessing the correlation between M1/M2 macrophage polarization determined by tumor immunohistochemistry analysis and [18F]DPA-714 PET/CT binding (qualitative and texture analysis) in patients with operable triple negative breast cancer.

Read the detailed description

The purpose of this study is to evaluate the correlation of inflammation assessed by M1/M2 macrophage polarization determined by tumor immunohistochemistry analysis and [18F] DPA-714 PET imaging by using qualitative and image texture analysis in patients with triple negative breast cancer.

Patients receive pre-therapeutic diffusion-weighted breast MRI (Magnetic resonance imaging) and 18FDG (fluorodeoxyglucose) PET/CT (Positron Emission Tomography/Computerized Tomography) scan within 30 days before enrollment.

[18F] DPA-714 PET/CT scan is performed before surgery. About 3 MBq/Kg of [18F] DPA-714 are injected intravenously, two acquisition sequences are performed following injection and 60 minutes after injection in order to evaluate early and late tumor uptake of [18F] DPA-714.

Surgery is scheduled after [18F] DPA-714 PET/CT scan. Tissue samples from breast surgery are used to assess M1 and M2 macrophages expression and to perform tumor molecular subtyping by Immunohistochemical analysis. Tumor Autoradiography with the TSPO (18 kDa Translocator Protein) ligand [18F]DPA-714 will be also assessed on tumor tissue.

A blood sample is performed before [18F] DPA-714 PET/CT scan in order to assess the genotyping of TSPO (18 kDa Translocator Protein) gene.

03

Conditions studied

  • Triple Negative Breast Cancer

Keywords

  • [18F]-DPA-714
  • PET/CT scan
  • 18 kDa Translocator Protein (TSPO)
  • Macrophages M1 and M2
  • Immunohistochemical analysis
  • MRI
  • Tumor Autoradiography
  • Tumor molecular subtyping
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 Years and older
  • Triple negative primary breast cancer based on immunohistochemical results as follows:

    • Estrogen receptor \< 10%
    • And Progesterone receptors \< 10%
    • And (Human Epidermal Growth Factor Receptor-2) not amplified or not overexpressed
  • Patient with a primary tumor eligible for primary surgery
  • Performance Status equal to 0 or 1
  • Fertile patients must use effective
  • Patient must be affiliated to a Social Health Insurance
  • Written

Exclusion criteria

Exclusion Criteria:

  • Patient with No triple negative breast cancer
  • Patient with inflammatory breast cancer
  • Patient with breast cancer
  • Patient receiving cancer treatments such as chemotherapy, immunotherapy, biologic response modifiers, hormonal therapy, and radiotherapy BEFORE the and PET scans are performed
  • Treated diabetes with fasting blood glucose > 10 mmol/L
  • Patient who received antibiotics and/or steroidal and/or non-steroidal anti-inflammatory drugs within 30 days PRIOR to [18F]-DPA-714 PET scan
  • to MRI (implants or metallic prosthesis, severe claustrophobia, pacemaker ...)
  • Patient deprived of liberty, under a measure of safeguard of justice, under guardianship or under the authority of a guardian
  • Pregnant or nursing patient
  • Agitation; impossibility of lying motionless for at least 1 hour, or known claustrophobia
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    [18F]-DPA-714 PET/CT

    \[18F\]-DPA-714 PET/CT scan

    Drug: [18F]-DPA-714

Interventions

  • Drug[18F]-DPA-714

    \[18F\]-DPA-714

06

What researchers measure

Primary outcomes

  1. Number of Participants With Predominance of M2-Polarized Macrophages

    Intratumoral macrophages were quantified by immunohistochemistry on surgical tumor specimens. CD68-positive cells were used to quantify the total macrophage population (M1 and M2 macrophages), whereas CD163-positive cells were used to identify M2-polarized macrophages. The percentage of M2 macrophages was calculated as the proportion of CD163-positive cells among all CD68-positive macrophages. Results are presented as the number of participants whose tumors showed a predominance of M2-polarized macrophages.

    Time frame: 2 months

  2. Correlation Between % M2 Using CD163 and SUV Max [18F]DPA-714 PET/CT

    The correlation between the percentage of CD163-positive M2 macrophages (determined by immunohistochemistry) and tumor SUVmax on \[18F\]DPA-714 PET/CT was assessed using Spearman's rank correlation coefficient.

    Time frame: 2 months

  3. Correlation Between CD68-Positive Macrophage Infiltration and Tumor SUVmax on [18F]DPA-714 PET/CT

    The correlation between intratumoral CD68-positive macrophage infiltration (assessed by immunohistochemistry) and tumor SUVmax on \[18F\]DPA-714 PET/CT was evaluated using Spearman's rank correlation coefficient.

    Time frame: 2 months

Secondary outcomes

  1. Distribution of [18F]DPA-714 PET/CT Tumor Uptake Patterns According to TSPO Genotype (HAB = High Affinity Binder, MAB = Mixed Affinity Binder and LAB = Low Affinity Binder)

    Tumor uptake patterns were classified as above, equal to, or below muscular background and are presented descriptively according to TSPO genotype (HAB, MAB, LAB). No formal statistical analysis was performed because of the limited sample size.

    Time frame: 2 months

  2. Slope of Tumor Time-Activity Curves During Early [18F]-DPA-714 PET/CT Acquisition

    Early tumor uptake was assessed using dynamic PET/CT time-activity curves (TACs). Results are presented as the slope of tracer accumulation derived from tumor TACs. Tumors were classified relative to the contralateral pectoral muscle as above muscular, equal to muscular, or below muscular background.

    Time frame: 1 month

  3. Primary Tumor Detection by [18F]-DPA-714 PET/CT, 18F-FDG PET/CT, and Diffusion-Weighted Breast MRI

    Primary tumor detection was assessed qualitatively using \[18F\]-DPA-714 PET/CT, 18F-FDG PET/CT, and diffusion-weighted breast MRI. Results are presented as the number of participants in whom the primary tumor was identified by each imaging modality.

    Time frame: 1 month

  4. [18F]-DPA-714 Toxicity

    Number of patients with adverse events and serious adverse event after \[18F\]-DPA-714 administration

    Time frame: 1 month

  5. Tumor SUVmean During Late [18F]-DPA-714 PET/CT Acquisition

    Late tumor uptake was assessed during the plateau phase of dynamic \[18F\]-DPA-714 PET/CT time-activity curves (TACs). Tumors were classified relative to the contralateral pectoral muscle as above muscular, equal to muscular, or below muscular background. Results are presented as median SUVmean values and ranges for each uptake pattern.

    Time frame: 1 month

07

Results

Posted Nov 10, 2026

Participant flow

Participant flow — Overall Study
Milestone[18F]-DPA-714 PET/CT
Started13
Completed13
Not completed0

Outcome measures

PrimaryNumber of Participants With Predominance of M2-Polarized Macrophages

Intratumoral macrophages were quantified by immunohistochemistry on surgical tumor specimens. CD68-positive cells were used to quantify the total macrophage population (M1 and M2 macrophages), whereas CD163-positive cells were used to identify M2-polarized macrophages. The percentage of M2 macrophages was calculated as the proportion of CD163-positive cells among all CD68-positive macrophages. Results are presented as the number of participants whose tumors showed a predominance of M2-polarized macrophages.

Time frame:
2 months
Reported as:
Count of participants · Participants
Number of Participants With Predominance of M2-Polarized Macrophages
Participants[18F]-DPA-714 PET/CT
Preponderance of M2-polarised macrophages11
Non preponderance of M2-polarised macrophages2
PrimaryCorrelation Between % M2 Using CD163 and SUV Max [18F]DPA-714 PET/CT

The correlation between the percentage of CD163-positive M2 macrophages (determined by immunohistochemistry) and tumor SUVmax on \[18F\]DPA-714 PET/CT was assessed using Spearman's rank correlation coefficient.

Time frame:
2 months
Reported as:
Number · Spearman correlation coefficient
Correlation Between % M2 Using CD163 and SUV Max [18F]DPA-714 PET/CT
Spearman correlation coefficient[18F]-DPA-714 PET/CT
Correlation Between % M2 Using CD163 and SUV Max [18F]DPA-714 PET/CT-0.45
PrimaryCorrelation Between CD68-Positive Macrophage Infiltration and Tumor SUVmax on [18F]DPA-714 PET/CT

The correlation between intratumoral CD68-positive macrophage infiltration (assessed by immunohistochemistry) and tumor SUVmax on \[18F\]DPA-714 PET/CT was evaluated using Spearman's rank correlation coefficient.

Time frame:
2 months
Reported as:
Number · Spearman correlation coefficient
Correlation Between CD68-Positive Macrophage Infiltration and Tumor SUVmax on [18F]DPA-714 PET/CT
Spearman correlation coefficient[18F]-DPA-714 PET/CT
Correlation Between CD68-Positive Macrophage Infiltration and Tumor SUVmax on [18F]DPA-714 PET/CT-0.30
SecondaryDistribution of [18F]DPA-714 PET/CT Tumor Uptake Patterns According to TSPO Genotype (HAB = High Affinity Binder, MAB = Mixed Affinity Binder and LAB = Low Affinity Binder)

Tumor uptake patterns were classified as above, equal to, or below muscular background and are presented descriptively according to TSPO genotype (HAB, MAB, LAB). No formal statistical analysis was performed because of the limited sample size.

Time frame:
2 months
Reported as:
Count of participants · Participants
Distribution of [18F]DPA-714 PET/CT Tumor Uptake Patterns According to TSPO Genotype (HAB = High Affinity Binder, MAB = Mixed Affinity Binder and LAB = Low Affinity Binder)
ParticipantsHAB (High Affinity Binder)MAB (Mixed Affinity Binder)LAB (Low Affinity Binder)
Above muscular background220
Equal to muscular background331
Below muscular background011
SecondarySlope of Tumor Time-Activity Curves During Early [18F]-DPA-714 PET/CT Acquisition

Early tumor uptake was assessed using dynamic PET/CT time-activity curves (TACs). Results are presented as the slope of tracer accumulation derived from tumor TACs. Tumors were classified relative to the contralateral pectoral muscle as above muscular, equal to muscular, or below muscular background.

Time frame:
1 month
Reported as:
Number · TAC slope
Slope of Tumor Time-Activity Curves During Early [18F]-DPA-714 PET/CT Acquisition
TAC slopeEarly [18F]-DPA-714 PET Acquisition
Above muscular background1.35
Equal to muscular background0.62
Below muscular background0.22
SecondaryPrimary Tumor Detection by [18F]-DPA-714 PET/CT, 18F-FDG PET/CT, and Diffusion-Weighted Breast MRI

Primary tumor detection was assessed qualitatively using \[18F\]-DPA-714 PET/CT, 18F-FDG PET/CT, and diffusion-weighted breast MRI. Results are presented as the number of participants in whom the primary tumor was identified by each imaging modality.

Time frame:
1 month
Reported as:
Count of participants · Participants
Primary Tumor Detection by [18F]-DPA-714 PET/CT, 18F-FDG PET/CT, and Diffusion-Weighted Breast MRI
Participants[18F]-DPA-714 PET/CT18FDG PET/CTDiffusion-weighted MRI
Primary Tumor Detection by [18F]-DPA-714 PET/CT, 18F-FDG PET/CT, and Diffusion-Weighted Breast MRI131313
Secondary[18F]-DPA-714 Toxicity

Number of patients with adverse events and serious adverse event after \[18F\]-DPA-714 administration

Time frame:
1 month
Reported as:
Count of participants · Participants
[18F]-DPA-714 Toxicity
Participants[18F]-DPA-714
Serious adverses events (SAEs) — Patients with adverses events AEs0
Serious adverses events (SAEs) — Patients who did not experience any AEs13
Adverses events (AEs) — Patients with adverses events AEs0
Adverses events (AEs) — Patients who did not experience any AEs13
SecondaryTumor SUVmean During Late [18F]-DPA-714 PET/CT Acquisition

Late tumor uptake was assessed during the plateau phase of dynamic \[18F\]-DPA-714 PET/CT time-activity curves (TACs). Tumors were classified relative to the contralateral pectoral muscle as above muscular, equal to muscular, or below muscular background. Results are presented as median SUVmean values and ranges for each uptake pattern.

Time frame:
1 month
Reported as:
Median · SUVmean
Tumor SUVmean During Late [18F]-DPA-714 PET/CT Acquisition
SUVmeanLate [18F]-DPA-714 PET Acquisition
Above muscular background4.02 (2.09 to 5.31)
Equal to muscular background1.66 (0.93 to 3.07)
Below muscular background0.61 (0.43 to 1.02)

Adverse events

Collected over 1 month. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
[18F]-DPA-714 PET/CT0/13 (0%)0/13 (0%)0/13 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)[18F]-DPA-714 PET/CT
<=18 years0
Between 18 and 65 years7
>=65 years6
Sex: Female, Male
Sex: Female, Male(Participants)[18F]-DPA-714 PET/CT
Female13
Male0
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)[18F]-DPA-714 PET/CT
Region of Enrollment
Region of Enrollment(participants)[18F]-DPA-714 PET/CT
France13
08

Study locations

3 sites
  • APHP - Hôpital Tenon
    Paris, 75020, France
  • Institut de cancerologie de l'Ouest
    Saint-Herblain, 44805, France
  • CHU Bretonneau
    Tours, 37044, France
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Jul 2021, 13 months.

Results were first posted in Nov 2026, 5 years 3 months after primary completion.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's 13 months is below that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2020
First posted
Mar 24, 2020
StartActual
Jun 11, 2020
Primary completionActual
Jul 21, 2021
CompletionActual
Jul 21, 2021
Results first posted
Nov 10, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 10, 2026
Sites
1 site added, 1 site removed
Show site
  • Institut de cancerologie de l'Ouest · Saint-Herblain, France
Show 1 removed
  • Institut de cancerologie de l'Ouest · Saint Herblain, France
Nov 10, 2026
Interventions
Changed [18F]-DPA-714 PET/CT scan→[18F]-DPA-714. Arm changed [18F]-DPA-714→[18F]-DPA-714 PET/CT
Nov 10, 2026
Primary outcomes
1 edited, 2 added
What changed in the outcomes
  • EditedCorrelation between M1/Between % M2 macrophage polarizationUsing CD163 and SUV Max [18F]DPA-714 PET/CT bindingTime frame: 18 months → 2 months
  • AddedNumber of Participants With Predominance of M2-Polarized MacrophagesTime frame: 2 months
  • AddedCorrelation Between CD68-Positive Macrophage Infiltration and Tumor SUVmax on [18F]DPA-714 PET/CTTime frame: 2 months
Nov 10, 2026
Documents
Secondary outcomes
5 edited
What changed in the outcomes
  • EditedCorrelation betweenDistribution of [18F]DPA-714 PET/CT Tumor Uptake Patterns According to TSPO genotypingGenotype (HAB = High Affinity Binder, MAB = Mixed Affinity Binder and LAB = Low Affinity Binder) and [18F]DPA-714 PET/CT bindingTime frame: 18 months → 2 months
  • EditedAssess the valueSlope of early and lateTumor Time-Activity Curves During Early [18F]-DPA-714 PET/CT acquisitionsAcquisitionTime frame: 18 months → 1 month
  • EditedEvaluate the performance of the three types of imaging used in this study:Primary Tumor Detection by [18F]-DPA-714 PET/CT (early and late), 18FDG18F-FDG PET/CT, and diffusionDiffusion-weighted breastWeighted Breast MRI in the characterization of triple negative breast cancerTime frame: 18 months → 1 month
  • Edited[18F]-DPA-714 toxicityToxicityTime frame: 18 months → 1 month
  • ChangedBefore Perform tumor molecular subtypingNow Tumor SUVmean During Late [18F]-DPA-714 PET/CT AcquisitionTime frame: 18 months → 1 month
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Results posted
    1 site added, 1 site removed
    Show site
    • Institut de cancerologie de l'Ouest · Saint-Herblain, France
    Show 1 removed
    • Institut de cancerologie de l'Ouest · Saint Herblain, France
    Primary outcomes 1 edited, 2 added
    What changed in the outcomes
    • EditedCorrelation between M1/Between % M2 macrophage polarizationUsing CD163 and SUV Max [18F]DPA-714 PET/CT bindingTime frame: 18 months → 2 months
    • AddedNumber of Participants With Predominance of M2-Polarized MacrophagesTime frame: 2 months
    • AddedCorrelation Between CD68-Positive Macrophage Infiltration and Tumor SUVmax on [18F]DPA-714 PET/CTTime frame: 2 months
    Secondary outcomes 5 edited
    What changed in the outcomes
    • EditedCorrelation betweenDistribution of [18F]DPA-714 PET/CT Tumor Uptake Patterns According to TSPO genotypingGenotype (HAB = High Affinity Binder, MAB = Mixed Affinity Binder and LAB = Low Affinity Binder) and [18F]DPA-714 PET/CT bindingTime frame: 18 months → 2 months
    • EditedAssess the valueSlope of early and lateTumor Time-Activity Curves During Early [18F]-DPA-714 PET/CT acquisitionsAcquisitionTime frame: 18 months → 1 month
    • EditedEvaluate the performance of the three types of imaging used in this study:Primary Tumor Detection by [18F]-DPA-714 PET/CT (early and late), 18FDG18F-FDG PET/CT, and diffusionDiffusion-weighted breastWeighted Breast MRI in the characterization of triple negative breast cancerTime frame: 18 months → 1 month
    • Edited[18F]-DPA-714 toxicityToxicityTime frame: 18 months → 1 month
    • ChangedBefore Perform tumor molecular subtypingNow Tumor SUVmean During Late [18F]-DPA-714 PET/CT AcquisitionTime frame: 18 months → 1 month
    Interventions Changed [18F]-DPA-714 PET/CT scan→[18F]-DPA-714. Arm changed [18F]-DPA-714→[18F]-DPA-714 PET/CT
    + 1 other change: conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04320030
Collaborators
SIRIC ILIAD
Responsible party
Sponsor
First posted
Mar 24, 2020
Start date
Jun 11, 2020
Primary completion
Jul 21, 2021
Completion
Jul 21, 2021
Results posted
Nov 10, 2026
Last update
Nov 10, 2026

Study contacts

Caroline ROUSSEAU, MD, PhD
principal investigator · Institut de Cancerologie de l'Ouest

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion